Moreover, our provided protocols allow also high-throughput-applicability in terms of drug testings including subsequent histological/immunohistochemical readouts (such as classical Ki-67 indices or specific stainings regarding endocrine functionality) and thereby highly comparable applicability for personalized medical approaches in appropriate endocrine tumor boards. The gene discussed is MKI67; the disease is malignant endocrine neoplasm.